The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...

Takeda Pharmaceuticals has named Julie Kim as the first woman to lead the 244-year-old Japanese drugmaker, a rarity in senior ...

Julie Kim has been running Takeda’s US operations since 2022 and will assume the role of CEO in June next year, subject to shareholder approval.

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...

US President Donald Trump has warned BRICS nations against introducing a new currency or backing an alternative to the U.S.

Guidance for 2025 from UPS falls short of estimates. Altria Group, the maker of tobacco products, posts quarterly earnings in line with expectations. Fourth-quarter per-share earnings of 80 cents top ...

ADRs traded higher in the premarket on Thursday after the Japanese drugmaker raised its full-year outlook with its Q3 FY24 results and named Julie Kim, head of its U.S. business, as the company’s next ...